Experimental drug combo aims to boost pancreatic cancer treatment
NCT ID NCT06639724
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding the drug fostamatinib to standard chemotherapy can help people with resectable pancreatic cancer. Fostamatinib is already approved for a blood disorder but has not been tried in pancreatic cancer. The study will enroll 36 participants to see if the combination is safe and does not delay surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fostamatinib (a Syk inhibitor) combined with gemcitabine and nab-paclitaxel chemotherapy
What this could lead to
If it works, this could point toward a new treatment option for resectable pancreatic cancer that may improve outcomes when added to standard chemotherapy.
What could go wrong
This is a very early phase 1b trial with only 36 participants, so it is primarily testing safety and feasibility. The drug has not been studied in pancreatic cancer before, and it may not improve outcomes or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••